Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Antonia Potarca"'
Autor:
Peter A. Merkel, John Niles, Richard Jimenez, Robert F. Spiera, Brad H. Rovin, Andrew Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker, for the CLASSIC Investigators
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 11, Pp 662-671 (2020)
Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment
Externí odkaz:
https://doaj.org/article/bb81072b122a4bb88073ca8840742823
Autor:
Thomas J. Schall, Pirow Bekker, Classic Investigators, Andrew S. Bomback, Brad H. Rovin, Christian Pagnoux, John L. Niles, Robert Spiera, Antonia Potarca, Peter A. Merkel, Richard A.H. Jimenez
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 11, Pp 662-671 (2020)
ACR Open Rheumatology
ACR Open Rheumatology
Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with g
Autor:
Annette Bruchfeld, Hasan Magin, Patrick Nachman, Samir Parikh, Richard Lafayette, Antonia Potarca, Shichang Miao, Pirow Bekker
Background Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b34dde9ad9db77f829c60c4c0f0bdc
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-183928
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-183928
Autor:
Thomas J. Schall, Michel Jadoul, David Jayne, Franziska Grundmann, Patrick B. Hamilton, Matthias Schaier, Lorraine Harper, Vladimír Tesař, Annette Bruchfeld, Pirow Bekker, Mårten Segelmark, Antonia Potarca, Istvan Szombati, Michael Venning, Volker Burst
Publikováno v:
Journal of the American Society of Nephrology. 28:2756-2767
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administere
Autor:
Peter A. Merkel, Antonia Potarca, David Jayne, Masayoshi Harigai, Jan Hillson, Thomas J. Schall, Pirow Bekker
Publikováno v:
Rheumatology. 58
Publikováno v:
Nephrology Dialysis Transplantation. 33:i85-i86
Autor:
Thomas J. Schall, Andrea Wang-Gillam, Deng Jun, Shichang Miao, Ferry A.L.M. Eskens, Aram F. Hezel, Ingrid M.E. Desar, David C. Linehan, Marcus Smith Noel, Johanna W. Wilmink, Janet Diehl, Frans L. G. Erdkamp, Niky Zhao, Antonia Potarca, Rajinder Singh, Jan Hillson, Stefan Sleijfer, Pirow Bekker
Publikováno v:
Journal of Clinical Oncology. 36:92-92
92 Background: The CCL2-CCR2 signaling axis may facilitate migration of myeloid derived suppressor cells to pancreatic cancer resulting in an immune suppressive tumor microenvironment. CCR2 inhibition in patients with non-metastatic pancreatic cancer
Autor:
Dick, de Zeeuw, Pirow, Bekker, Elena, Henkel, Christopher, Hasslacher, Ioanna, Gouni-Berthold, Heidrun, Mehling, Antonia, Potarca, Vladimir, Tesar, Hiddo J Lambers, Heerspink, Thomas J, Schall, A, Woodman
Publikováno v:
Lancet Diabetes & Endocrinology, 3(9), 687-696. ELSEVIER SCIENCE INC
Summary Background Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a20ed6401454c1bf70b854352a1f9ec1
https://research.rug.nl/en/publications/0e075502-4829-4112-963c-6d47c99c6649
https://research.rug.nl/en/publications/0e075502-4829-4112-963c-6d47c99c6649
Autor:
Pirow Bekker, Antonia Potarca, Annette Bruchfeld, Patrick H. Nachman, Richard A. Lafayette, Lisa Lohr, Samir M. Parikh, Thomas J. Schall, Shichang Miao, Janet Diehl
Publikováno v:
Nephrology Dialysis Transplantation. 32:iii82-iii82
Autor:
Antonia Potarca, Stefan Sleijfer, Janet Diehl, Lisa Lohr, Rajinder Singh, David C. Linehan, Thomas J. Schall, Pirow Bekker, Shichang Miao, Ferry A.L.M. Eskens, Johanna W. Wilmink, Niky Zhao, Aram F. Hezel, Israel F. Charo, Frans L. G. Erdkamp, Marcus Smith Noel, Andrea Wang-Gillam, Deng Jun, Ingrid M.E. Desar
Publikováno v:
Journal of Clinical Oncology. 35:276-276
276 Background: CCR2 inhibition decreases tumor-associated macrophages and Treg cells, and increases CD8+ and CD4+ T cells in pancreatic tumors. Single oral doses of 150 mg CCX872-B were well tolerated in patients with pancreatic cancer. The first st